Picture supply: Getty Photographs
There’s been numerous give attention to Diageo’s (LSE: DGE) weak gross sales development in Latin America just lately. This challenge has despatched the share value sharply decrease.
But weak gross sales in Latin America aren’t the one challenge right here. There’s one other problem the corporate’s going through, and I’m attempting to work out if it’s factored into the share value at this time.
Decrease demand for alcohol?
The problem I’m referring to is the rising reputation of GLP-1 diabetes and weight reduction medicine developed by the likes of Novo Nordisk and Eli Lilly.
Analysis is displaying that these medicine have a tendency to scale back alcohol cravings, and result in a lowered want to drink.
One research, revealed late final 12 months, noticed a “considerably decrease” self-reported consumption of alcohol and drinks per consuming episode.
There’s additionally hypothesis that the medicine have a much bigger affect on the need to eat liquor relative to the need to eat beer.
Writing about Diageo rival Brown-Forman (the proprietor of Jack Daniels) final week, CNBC host Jim Cramer mentioned: “I believe this inventory is completely susceptible given GLP-1 and hashish. The brand new GLP-1 diabetes and weight reduction medicine affect the need to drink onerous alcohol. However not a lot beer.”
The issue for Diageo and the opposite alcoholic beverage firms is that there might be numerous folks taking these medicine within the years forward.
In line with JP Morgan, 30m folks within the US (Diageo’s largest market) might be taking them by 2030. That will characterize about 9% of the inhabitants. If that many individuals have been taking these medicine, Diageo’s development may doubtlessly gradual.
So these medicine create some uncertainty right here. And it’s onerous to know if that is baked into the share value and valuation already. Probably not, on condition that the forward-looking price-to-earnings (P/E) ratio is about 18.
A number of development drivers
Now, I’ll level out that not everyone seems to be as bearish as Cramer in relation to the GLP-1 medicine. Analysts as Bernstein, for instance, consider there’s not numerous overlap between the ‘tremendous person’ of alcohol (somebody who consumes lots) and the GLP-1 goal client.
And there are many different long-term development drivers that would offset any potential GLP-1-related weak spot. For instance, spirits proceed to achieve market share from beer. One motive for that is that numerous shoppers really feel that spirits are extra aligned with their well being/calorie targets.
Diageo can be a serious participant within the tequila area due to its Don Julio model. And proper now, tequila is the fastest-growing spirits class on the earth.
Then there’s the growing international inhabitants and rising wealth within the rising markets. This might assist to assist gross sales within the years forward.
I’m holding
Given these constructive components, I don’t plan to promote my Diageo shares any time quickly. Nonetheless, I’ll be carefully monitoring the GLP-1 challenge. It does add some danger to the funding case.
